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Summary
Though social networks are known to play an important role in drug-using behaviors associated
with HCV infection, literature on social networks and HCV is inconsistent. This exploratory study
examined HCV RNA distribution within a social network of anti-HCV positive rural Appalachia
nonmedical prescription opioid users (NMPOUs). Participants were tested serologically for HCV
RNA, and behavioral, demographic, and network data were collecting using interview-
administered questionnaires. Multivariate analyses were performed using logistic regression.
Behavioral and demographic characteristics did not differ by RNA status. In the multivariate
model, recent injection drug users were more likely to be RNA-positive (OR: 4.06, 95% CI: 1.04 –
15.83), and turnover into one’s drug network was significantly protective (OR: 0.15, 95% CI:
0.03-0.75). This is the first study to date to examine HCV distribution among rural NMPOUs from
a network perspective and demonstrates that network characteristics significantly contribute to the
epidemiology of HCV in this understudied, high-risk population.
Introduction
Hepatitis C (HCV) is the most common blood-borne infection in the US, with an estimated
3.2 million people chronically infected [1]. Injection drug use is a well-established risk
factor for blood-borne infection [e.g. 2-3]. In fact, as many as 90% of injection drug users
(IDUs) are infected with HCV within five years of initiating injection [4]. Injection drug use
and its associated risk, however, do not occur in isolation; they are heavily influenced by the
structure and composition of the social networks in which they arise [5-6].
IDUs’ risk behavior and susceptibility to infection is strongly influenced by that of their
network members [7-10]. For example, an individual’s injection behavior is influenced by
their exposure to other IDUs [11-12], particularly those who are friends [13], sex partners
[14-15], or family members [16]. Previous research has also demonstrated an interrelated
relationship [6] between large network size [10, 17], high network density [e.g. 10, 17-18],
and high network turnover (e.g. people leaving or entering one’s network) [19] and risk
behavior among IDUs. The centrality of a drug user within his/her social network, as well as
the types of relationships he/she has with network members can also play a role in risk
behavior [5-6].
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The growing recognition of social networks’ contribution to IDUs’ risk for HCV has led to a
number of molecular epidemiological studies in which HCV RNA and genotype testing is
conducted within networks [20-23]. While the literature on drug users’ social networks
consistently demonstrates a link between network structure and engagement in HCV risk
behavior [6], such findings have yet to be consistently substantiated by molecular
epidemiological research examining HCV transmission within social networks of IDUs. For
example, a recent study examining HCV genotype homology between dyads and
recruitment chains generated from respondent-driven sampling (RDS) of IDUs found that
individuals within recruitment dyads and/or chains had no more genetic similarity in their
HCV infection than did those with more distant relationships [20]. Similarly, a study
involving social network analysis and HCV phylogenetic analysis of Australian IDUs found
a low level of correlation between drug users’ social distance and the genetic relatedness of
their HCV infections [21]. On the other hand, a phylogenetic analysis of HCV-positive
patients in a surveillance program in Brazil concluded that different HCV subtypes were
characterized by different social networks [22]. A social network study of IDUs by Aitken
and colleagues (2009) concluded that positive HCV antibody status was associated with
having more network members who were age 18 or older when they initiated IDU and with
having other network members who were antibody positive. Positive HCV RNA status was
also associated with having network members who were HCV RNA positive [23].
Given the inconsistencies in the extant literature, more research examining the distribution
of HCV infection within social networks of drug users is warranted. Previous studies have
primarily focused on heroin users [21, 23], cocaine users [6], and syringe exchange program
recipients [6] in urban, international settings [6, 20-23]. To our knowledge, no study has
examined HCV RNA distribution in its association with social network characteristics
among nonmedical prescription opioid users (NMPOU). Moreover, there is a substantial gap
in previous research involving populations of rural drug users. Nonmedical prescription
opioid use has become particularly problematic in the rural Appalachian region of Kentucky
[e.g. 24-25], and evidence suggests that many drug users in the region are administering the
prescription drugs via injection [24]. Given the increased risk of HCV transmission
associated with injection drug use, a better understanding of the molecular and social
epidemiology of HCV in this high-risk, understudied population of rural drug users is
needed. The purpose of this exploratory study is two-fold: to examine the distribution of
HCV RNA positive drug users within a network of NMPOU in rural Appalachian Kentucky,
and to examine the association of their individual-level, egocentric and sociometric risk
network characteristics with HCV RNA status.
Methods
Study sample
The study sample was drawn from a larger cohort of rural Appalachian nonmedical
prescription opioid users (N=436). The overall purpose of the longitudinal cohort study is to
determine the prevalence and incidence of HCV, HIV and herpes simplex-2 virus in the
context of rural drug and sex networks. A storefront location in a rural Appalachian town of
approximately 5,000 residents was used for participant recruitment and interviews.
Recruitment was conducted using RDS, which is often the most feasible and appropriate
sampling technique for hidden populations such as drug users [26]. Seeds for the RDS were
identified through outreach workers, community informants, and through flyers posted in
town and outside the study field office. Upon completion of the baseline interview, seeds
were given three coupons to bring in additional network members. Individuals who
redeemed the coupons were then given coupons to recruit additional members and so on
until the desired sample size was achieved. The seeds were given $10 for each referred
network member who redeemed their coupon and completed the baseline interview.
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Study recruitment began in November, 2008 and was completed in August, 2010. Eligibility
criteria for the study included those who were at least 18 years of age, were residents of an
Appalachian county and had used at least one of the following drugs to get high in the prior
30-day period: prescription opioids, heroin, crack/cocaine and/or methamphetamine. An
interviewer-administered questionnaire was utilized to determine self-reported behaviors.
Data were entered by the interviewers directly onto a touch screen laptop loaded with
computer-assisted personal interviewing (CAPI) software. Participants are compensated $50
for each study visit and the Institutional Review Board at the University of Kentucky
approved the protocol.
Drug network data collection
A name-generating questionnaire (first name and last initial) was used to determine with
whom individuals had used injected and non-injected drugs in the past 6 months (excluding
alcohol and marijuana). For each person named, additional information about the person was
gathered, including their gender, race and approximate age. Four sources of information
were used to confirm network ties. The name and demographic characteristics were checked
against those of other participants in the study. A match in the name and demographic
information was considered a confirmed linkage. Linkages that could not be confirmed
using names and demographic information were then matched against information provided
by individuals screened for eligibility. Participants screened for study participation (n=939)
provided detailed demographic information for the purposes of network linkage
confirmation. Finally, advice from community-based research staff was sought to determine
and confirm network linkages. Linkages that could not be confirmed using one of these were
not included in the sociometric network. These methods are similar to that used in previous
research [27]. UCInet 6.303 [28] was used for network analyses.
In addition to examining the overall drug network, participants’ injection risk network was
also examined. Once participants’ drug network members were established, participants
were asked about their injection behavior with each network neighbor. Participants were
asked if in the past six months they had injected drugs with the person and/or if they had
shared injection equipment (e.g. syringes, cookers, rinse water) with the person in the past
six months. A sociometric network, hereinafter called “injection risk network”, was
constructed in which a tie constituted any relationship in which at least one person reported
injecting together or sharing injection equipment.
Egocentric network variables
Four egocentric network characteristics were examined for their associations with HCV
RNA status. Egocentric network size is merely a count of all the network members (alters)
linked to a focal individual (ego), not including the ego themselves. For example, egocentric
drug network size was determined by the number of individuals with whom the participant
reported using drugs in the past six months. For analysis of egocentric drug network size
was categorized into ‘high’ (greater than 2) and ‘low’ (less than or equal to 2). The density
of participants’ drug network was calculated as the proportion of possible connections
present in one’s ego network. Participants with a density of zero were classified as having
low density and participants with density greater than or equal to one were classified as
having ‘high density’.
Turnover (both in and out) of participants’ drug networks was also assessed. Network
turnover in and out was defined as a gain and loss, respectively, in network members
between baseline and 6-month follow-up assessments. For computation of turnover, drug
network isolates were excluded (n=49). Also, participants who had not yet completed their
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6-month follow-up assessment at the time of their serological testing for HCV RNA were
excluded (n=6). Turnover was analyzed as continuous.
Sociometric network variables
Homophily was computed by testing if individuals who were HCV RNA positive are more
likely to be tied to each other in a network of drug relations than that which would be
expected at random. Homophily was also computed to test if individuals who were RNA
negative were more likely to be tied to each other than would be expected at random.
Homophily is computed by comparing the observed network against 20,000 permutations of
random networks and the output is identical to that of a Pearson Correlation table.
Homophily testing was performed with the Join-Count command in UCInet 6.30 [28].
Four measures were used to examine participants’ centrality within their drug networks:
degree centrality, eigenvector, betweenness, and 2-step reach. Degree centrality, the number
of network members adjacent to a given participant in the network [29], was dichotomized
into ‘high’ (centrality greater than 2) and ‘low’ (centrality less than or equal to 2).
Eigenvector centrality [30] takes into account participants’ second order connections and the
interconnectedness of those connections. Considering the second-order dimension of
individuals’ connections is especially important in networks involving risk behaviors that
facilitate the diffusion of infectious disease, as an individual whose friends are engaged in
risky behaviors with multiple others are more likely to infect an individual and/or be
infected than an individual whose friends do not engage in risk behaviors with other people
[31]. Eigenvector values were dichotomized (0 = eigenvector of 0, 1= eigenvector greater
than 0).
Betweenness served as a measure of how often the participant lies on the shortest ‘path’
between two nodes within the drug network. Due to the skewed distribution of the data, drug
network betweenness was dichotomized according to a median split (‘low’: less than 17.2,
‘high’: greater than or equal to 17.2). Two-step reach was used to represent the number of
network members who are within two network linkages from the participant. Due to
distribution, drug network two-step reach was also dichotomized into ‘high’ and ‘low’
groups by a median split (‘low’: less than 6, ‘high’: greater than or equal to 6).
K-cores were used to examine sub groups within the drug network that were more connected
than others. This method was originally used to assess HIV risk by Freidman and colleagues
(1997) [8]. Consistent with the aforementioned study by Friedman and colleagues (1997),
drug k-coreness was dichotomized into ‘high’ (k-coreness equal to or greater than 2) and
‘low’ (k-coreness equal to 0 or 1). Of note, participants with k-coreness equal to 0 were
isolates in the network.
To assess participants’ proximity to other actors in their risk and drug networks who engage
in risk behavior (lifetime injection drug use and injection drug use within the past 6 months),
as well as to actors who are anti-HCV positive, geodesic distance was computed. Geodesic
distance is the length of the shortest path between a given pair of members in the network
[29]. Individuals who are “unreachable”, meaning they lack any connections to given
individual with X characteristic, were excluded from analyses of geodesic distance. Given
the risk conferred by being immediately connected to a person engaging in risk behavior or
already exposed to HCV, geodesic distance variables were dichotomized, where 1=one step
removed from [HCV, IDU], 0=two or more steps removed from [HCV, IDU].
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Serological testing for detection of HCV RNA
During their baseline visits, all participants consented to HCV antibody testing. Testing was
performed using the Home Access test for HCV antibody, a third-generation enzyme
immunoassay conducted on dried blood spot specimens collected by finger-stick. The
accuracy of the Home Access test has been demonstrated [32]. The baseline prevalence of
anti-HCV was 45.9% (n=200). Participants were provided with post-test counseling tailored
to their study result and were also provided with a list of treatment referrals in the area,
where appropriate.
The sampling procedure for HCV RNA testing is described in detail elsewhere [33]. A
randomly selected sample (n=81) of anti-HCV positive participants were tested for HCV
RNA using COBAS® Ampliprep/COBAS® TaqMan® HCV test kit (Roche Molecular
Systems, Inc), which uses real-time polymerase chain reaction (PCR), transcription-
mediated amplification (TMA), and multi-probe reverse hybridization of the 5’ untranslated
region (5’ UTR) of the HCV genome. Testing was performed by Quest Diagnostics Nichols
Institute (Chantilly, VA). An IRB-approved post-test counseling protocol was administered
to participants.
The randomly selected sample of participants who were tested for HCV RNA were
representative of the overall pool of anti-HCV positive participants in terms of demographic
characteristics (gender, age, education, insurance status), health (self-reported health status,
lifetime number of hospitalizations), lifetime number of incarcerations, and HCV risk
behaviors (having ever injected drugs, having ever shared equipment for snorting drugs, and
having ever received a blood transfusion or tattoo).
Assessment of demographic and behavioral correlates
Participants’ demographic characteristics (see Table 1) were based on their baseline
assessment in the study, while behavioral characteristics were extracted from their most
recently completed interview (i.e. baseline, 6-month, 12-month, or 18-month interview). The
average time which had elapsed between participants’ most recent interview date and the
date of their blood draw was 51.7 days (SD 41.1; range: 18 – 140).
Analysis
Bivariate analyses comparing HCV RNA positive to RNA negative participants were
performed using a series of chi-square tests for categorical variables and Wilcoxon sign-rank
tests for continuous variables (all variables were non-normally distributed). Multivariable
correlates to HCV RNA status were initially assessed using three logistic regression models.
Two demographic variables (e.g. age, gender) were chosen a priori to be entered into the
regression models based on extant literature that suggests they exert strong influences on
risk behavior at the interpersonal and network level [5-6]. Similarly, one individual-level
behavioral variable (injection drug use in the past 6 months) was chosen a priori to be
included in the regression analyses due to existing evidence of its strong association with
HCV transmission [e.g. 2-3]. The first model included only those three variables selected a
priori for analysis. The second and third models evaluated the association between RNA
status and egocentric and sociometric variables, respectively, while controlling for age,
gender, and injection drug use. Egocentric and sociometric variables were chosen for
inclusion in Models 2 and 3 based on their association with RNA status at p<.10 in bivariate
analyses. A fourth model containing sociometric and egocentric variables as well as age,
gender, and recent injection drug use was then estimated using a common backward
elimination strategy [34] to produce the most parsimonious final model. At each step of the
backward elimination strategy, the variable with the least significant association with RNA
status was dropped and the change in the -2 log likelihood between the reduced and final
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model was evaluated against a chi-square distribution with one degree of freedom. If there
was no significant change in the -2 log likelihood (i.e. model fit), the variable was
eliminated. This strategy was continued until the further elimination of variables would have
resulted in a significant change in model fit. Collinearity was assessed at each step of the
model-building process using a SAS macro which generates condition indexes and variance
decomposition proportions [34].
Results
Demographic characteristics of participants by HCV RNA status are displayed in Table 1.
The mean age of participants was 35 years (SD 8.3; range 21-53), the vast majority were
white (95%) and nearly 60% were male. Factors which could potentially inhibit ability to
seek care were common as 38% lacked access to transportation, 36% were unemployed, and
63% were uninsured. Half of the sample had graduated from high school and over one-third
(36%) were unemployed. RNA positive and negative participants did not differ
demographically.
Figure 1 displays the distribution of HCV RNA positive participants within the overall drug
risk network and in the injection risk sub-network. The injection risk network (visualized
with red ties in Figure 1) contained 40% (n=10) of the RNA negative participants and 59%
(n=33) of the RNA positive participants, but the difference was not statistically significant
(p=.115). The homophily value for the drug network was significant, however, indicating
that individuals who are HCV RNA positive are more likely to be tied to each other in the
network of drug relations than that which would be expected at random (p=.049), while
RNA negative participants were no more likely to be tied to other RNA negative participants
or to RNA positive participants than would be expected at random (p=.936 and p=.195,
respectively).
Egocentric and sociometric drug network characteristics of participants by HCV RNA status
are reported in Table 2. Participants who were HCV RNA positive had significantly higher
egocentric drug network density (p=.045) and reported somewhat less turnover into their
networks from baseline to six month follow-up than did RNA negative participants, though
the difference was not statistically significant (p=.085). Participants did not differ by HCV
RNA status on egocentric network size.
Multivariable correlates to HCV RNA status
Table 3 displays multivariable correlates to HCV RNA status. Model 1 contained only the
demographic variables and recent injection drug use; none of which were significantly
associated with RNA status. Models 2 and 3 extended Model 1 to include egocentric and
sociometric network variables, respectively, that were significant at p<.10 in previous
bivariate analyses. In Model 2, recent injection drug use and turnover into the drug network
were significantly associated with RNA status (p=.016 and p=.001, respectively). In Model
3, individual-level nor sociometric-level variables were statistically significant. In estimating
a final model, sociometric and egocentric variables could not be entered into the same model
due to collinearity. Thus, the final comprehensive model was estimated using a backward
elimination approach applied to Model 2. Age and gender were not retained in the model,
leaving recent injection drug use, egocentric network density, and network turnover. Recent
injection drug use was significantly associated with positive RNA status (OR: 4.06, 95% CI:
1.04 – 15.83, p=.044) and turnover into one’s drug network was negatively associated with
positive RNA status (OR: 0.15, 95% CI: 0.03 – 0.75, p=.020). Egocentric drug network
density was not significantly associated with RNA status (OR: 3.22, 95% CI: 0.87 – 11.95,
p=.081) after adjustment for the other variables in the model.
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HCV RNA positive participants in this study were demographically and behaviorally similar
to participants who were HCV RNA negative. However, in models controlling for age,
gender, and recent injection drug use, turnover into one’s drug network had a significantly
negative association with being RNA positive (OR: 0.06, 95% CI: 0.01 - 0.51). In the final
model recent injection drug use was associated with four times greater odds of HCV RNA
positive status (95% CI: 1.04 – 15.83), and turnover into one’s drug network remained
significantly protective (OR: 0.15, 95% CI: 0.03-0.75).
In this study, many egocentric and sociometric network characteristics identified in previous
research to be associated with HCV risk behavior (e.g. network size, density, centrality,
distance to IDUs) were not significantly associated with HCV RNA status [5-6]. However,
the findings regarding recent injection drug use were consistent with the wealth of evidence
that has shown it to be a strong risk factor for HCV infection [e.g. 2-3]. Notably, in the
present study, injection drug use was associated with RNA status only in the models which
controlled for egocentric characteristics. In the models controlling for demographic
characteristics and sociometric characteristics, injection drug use was not associated with
RNA status.
The negative association between positive RNA status and inward drug network turnover
(e.g. a gain in network members from baseline to 6-month follow-up) is not consistent
previous behavioral research which suggests that high network turnover is associated with
risky injection drug use behavior among network members [6, 19]. One possibility for the
association observed in this study could be that a high level of turnover into one’s network is
not necessarily an indication of network instability, given that network turnover-in was not
correlated with network turnover-out (r=.058, p=.466). HCV RNA positive participants may
be avoiding the expansion of their drug networks in an effort to avoid contact with
serodiscordant partners, a phenomenon known as “serosorting” that has been observed in
other research [35]. Conversely, participants who are RNA negative may be avoiding
contact with those who are RNA positive, thereby decreasing the latter’s opportunity for
network expansion. The homophily results from this study, which found that RNA positive
participants tended to ’flock together’ may also provide some evidence for serosorting. More
research, however, is needed to fully understand network turnover dynamics and HCV risk
in this population.
These findings highlight the potential of network-based interventions for HCV prevention
among IDUs. Specifically, these results indicate the importance of the participants’
egocentric network in HCV transmission. Therefore, peer-driven interventions could be
effective in reducing HCV risk behaviors in this population [36-38]. Though network
characteristics played an important role in drug users’ risk for active HCV infection, the role
of better access to clean syringes cannot be ignored. Previous research has shown that after
controlling for social network characteristics, syringe access/supply remains a significant
predictor of risk behavior [39]. This population is in critical need of improved access to
services that can reduce their long- and short-term risk for blood borne infection.
While this study provides important insight into the epidemiology of HCV infection in an
understudied, high-risk population of drug users and illuminates areas for future research, it
is not without limitations. For example, the study is limited by a small sample size.
However, it is notable that despite the sample size, statistically significant associations
between RNA status and egocentric network characteristics were observed. It is also worth
noting that this sample of drug users was randomly selected from a larger cohort of HCV
antibody drug users and was demographically and behaviorally representative of the larger
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sample. An additional limitation is posed by the use of self-report to collect all behavioral
data. However, self-reported drug and risk behaviors have been shown to be sufficiently
valid and reliable [40]. Issues of temporality also present a limitation to this study, as it
could not be determined if social network characteristics were a cause or consequence of
drug risk behavior and HCV status. To address this limitation, longitudinal social network
studies that track drug users’ HCV RNA status over time are needed.
Despite limitations, this study presents important evidence that the current paradigm of
understanding drug users’ risk for blood borne infection only within the context of their
individual-level risk factors may be inadequate for understanding HCV transmission in this
sample of rural drug users. Rather, these data suggest that drug use and its associated risks
are best understood within the social contexts in which they occur.
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HCV RNA status of randomly selected sample of anti-HCV positive drug users in a drug
risk network (n=222)
*Relationships in which network members injected together, shared needles, and/or shared
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Table 2
Egocentric and sociometric drug network characteristics of HCV RNA positive/negative drug users (n=81)
Variables RNA+ (n=56) n(%) RNA- (n=25) n(%) χ2 p-value
Egocentric variables
Network size greater than two 43 (76.8) 20 (80.0) 0.10 .748
High network density 29 (64.4) 8 (38.0) 4.04 .045*
Turnover (6-month)1
 Turnover-in 0.3 (0.0 - 0.9) 0.7 (0.2 - 1.0) z=1.72 .085
 Turnover-out 1.1 (0.3 - 1.6) 1.3 (0.7-1.8) z=1.08 .278
Sociometric variables
Centrality
 High degree centrality 43 (53.1) 20 (80.0) 0.10 .748
 High eigenvector centrality 51 (91.1) 5 (8.9) 0.18 .669
 High betweenness 36 (64.3) 16 (64.0) 0.00 .980
 High 2-step reach 45 (80.4) 15 (60.0) 3.73 .054
K-core of 2 or greater 39 (69.6) 15 (60.0) 0.72 .395
Located in main component 50 (89.3) 21 (84.0) 0.45 .504
Member of injection risk network 10 (40.0) 33 (58.9) 2.49 .115
Social distance of two steps or more from a network member who is:
 Anti-HCV positive (n=76) 43 (82.7) 22 (91.7) 1.07 .301
 Lifetime IDU (n=78) 51 (94.4) 23 (95.8) 0.07 .797
 Recent IDU (past 6 months) (n=74) 48 (90.6) 16 (76.2) 2.66 .103




For analysis of turnover, drug network isolates were excluded (n=155). Participants who had not yet completed their 6-month follow-up
assessment at the time of substudy participation were also excluded (n=6).
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Table 3
Multivariable correlates to HCV RNA status among rural Appalachian drug users
OR (95% CI) p-value
Model 1 (n=81)
 Age 0.99 (0.93 - 1.05) .703
 Gender 1.83 (0.65 - 5.15) .253
 IDU in past 6 months 2.49 (0.89 - 7.01) .084
Model 2 (n=56)
 Age 1.10 (0.98 - 1.23) .122
 Gender 4.60 (1.00 - 21.27) .051
 IDU in past 6 months 8.86 (1.50 - 52.36) .016
 Egocentric variables
  Egocentric drug network density 3.96 (0.93 - 16.94) .064
  Turnover into drug network 0.06 (0.01 - 0.51) .001
Model 3 (n=81)
 Age 0.98 (0.92 - 1.06) .627
 Gender 1.76 (0.57 - 5.43) .328
 IDU in past 6 months 2.01 (0.65 - 6.24) .228
 Sociometric variables
  Drug network 2-step reach 2.21 (0.74 – 6.64) .156
Final Model (n=56)
 IDU in past 6 months 4.06 (1.04 – 15.83) .044
 Egocentric variables
  Egocentric drug network density 3.22 (0.87 – 11.95) .081
  Turnover into drug network 0.15 (0.03 – 0.75) .020
OR: odds ratio, CI: confidence interval, IDU: injection drug use
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